Literature DB >> 12192009

Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor.

Ralf Geiben-Lynn1, Nancy Brown, Bruce D Walker, Andrew D Luster.   

Abstract

CD8(+) T-cells secrete soluble factor(s) capable of inhibiting both R5- and X4-tropic strains of human immunodeficiency virus type 1 (HIV-1). CCR5 chemokine ligands, released from activated CD8(+) T-cells, contribute to the antiviral activity of these cells. These CC-chemokines, however, do not account for all CD8(+) T-cell antiviral factor(s) (CAF) released from these cells, particularly because the elusive CAF can inhibit the replication of X4 HIV-1 strains that use CXCR4 and not CCR5 as a coreceptor. Here we demonstrate that activated CD8(+) T-cells of HIV-1-seropositive individuals modify serum bovine antithrombin III into an HIV-1 inhibitory factor capable of suppressing the replication of X4 HIV-1. These data indicate that antithrombin III may play a role in the progression of HIV-1 disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12192009     DOI: 10.1074/jbc.M207079200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages.

Authors:  Arevik Mosoian; Avelino Teixeira; Anthony A High; Robert E Christian; Donald F Hunt; Jeffrey Shabanowitz; Xinyan Liu; Mary Klotman
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  The CD8+ cell noncytotoxic anti-HIV response can be blocked by protease inhibitors.

Authors:  Carl E Mackewicz; Charles S Craik; Jay A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-06       Impact factor: 11.205

3.  The heparin-binding site of antithrombin is crucial for antiangiogenic activity.

Authors:  Weiqing Zhang; Richard Swanson; Gonzalo Izaguirre; Yan Xiong; Lester F Lau; Steven T Olson
Journal:  Blood       Date:  2005-05-19       Impact factor: 22.113

4.  Induction of a Soluble Anti-HIV-1 factor (s) with IFN-γ, IL-10, and β-Chemokine Modulating Activity by an Influenza-Bacterial Polyantigenic Mixture.

Authors:  José W Rodríguez; Nat O Pagan; María C Ocasio; Zilka Ríos; Luis A Cubano; Nawal M Boukli; Miguel Otero; Robert Hunter; Madhavan P Nair; Eddy Rios-Olivares
Journal:  Am J Infect Dis       Date:  2007

5.  CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition.

Authors:  Theresa Li-Yun Chang; Fleur François; Arevik Mosoian; Mary E Klotman
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

6.  Anti-HSV activity of serpin antithrombin III.

Authors:  Debra C Quenelle; Tracy L Hartman; Robert W Buckheit; Mark N Prichard; Ralf Geiben Lynn
Journal:  Int Trends Immun       Date:  2014-04

7.  Influenza Virus H1N1 inhibition by serine protease inhibitor (serpin) antithrombin III.

Authors:  Donald F Smee; Brett L Hurst; Craig W Day; Ralf Geiben-Lynn
Journal:  Int Trends Immun       Date:  2014-04-01

8.  Noncytotoxic suppression of human immunodeficiency virus type 1 transcription by exosomes secreted from CD8+ T cells.

Authors:  Ashwin Tumne; Varsha Shridhar Prasad; Yue Chen; Donna B Stolz; Kunal Saha; Deena M Ratner; Ming Ding; Simon C Watkins; Phalguni Gupta
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

9.  Protein kinase C and NF-κB-dependent CD4 downregulation in macrophages induced by T cell-derived soluble factors: consequences for HIV-1 infection.

Authors:  Rui André Saraiva Raposo; David C Trudgian; Benjamin Thomas; Bonnie van Wilgenburg; Sally A Cowley; William James
Journal:  J Immunol       Date:  2011-06-10       Impact factor: 5.422

10.  In vivo anti-HIV activity of the heparin-activated serine protease inhibitor antithrombin III encapsulated in lymph-targeting immunoliposomes.

Authors:  Mohammed Asmal; James B Whitney; Corinne Luedemann; Angela Carville; Robert Steen; Norman L Letvin; Ralf Geiben-Lynn
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.